CSPC Pharmaceutical Group Ltd (HKG: 1093), a leading pharmaceutical company based in China, has announced that the National Medical Products Administration (NMPA) has approved a supplementary market approval filing for its recombinant human TNK tissue-type plasminogen activator for injection (rhTNK-tPA). The drug is now approved for use as a thrombolytic therapy in patients suffering from acute ischemic stroke with an onset time of less than 4.5 hours, marking it as the first of its kind among similar products in China.
RhTNK-tPA, a recombinant protein derived from mammalian cells through genetic engineering, was initially launched in China in 2015 for use as a thrombolytic therapy for patients with acute myocardial infarction within six hours of onset. The drug offers significant clinical advantages as it can complete a single bolus intravenous injection within 5-10 seconds, compared to products that require initial intravenous bolus administration followed by a one-hour intravenous infusion.- Flcube.com
